fundvisualizer.com

WisdomTree BioRevolution ETFWDNA

Performance (before sales charge)

As of 01/31/2024

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 01/31/2024
Stock
82.66%
Non-U.S. Stock
17.34%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
0.00%
Other
0.00%

Due to rounding, percentages may not equal 100%.

Sectors

As of 01/31/2024

Basic materials

12.05%

Consumer cyclical

0.00%

Financial services

0.00%

Real estate

0.00%

Consumer defensive

3.55%

Health care

84.00%

Utilities

0.00%

Communication services

0.00%

Energy

0.00%

Industrials

0.00%

Technology

0.00%

Top 10 holdings

As of 01/31/2024

Twist Bioscience Corp
3.12%
Fate Therapeutics Inc
2.71%
Novozymes A/S Class B
2.38%
BridgeBio Pharma Inc
2.15%
Blueprint Medicines Corp
2.03%
Iovance Biotherapeutics Inc
2.01%
Vericel Corp
1.79%
Eli Lilly and Co
1.78%
Natera Inc
1.60%
Arcturus Therapeutics Holdings Inc
1.56%
Fund assets

$2.54 Million

Share class

--

Morningstar category

Health

Expense ratio

0.45%

Investment objective

Specialty - Health

Documents